Sugi Predict

Sugi Predict / Compounds / SCHEMBL11519

SCHEMBL11519

SCHEMBL11519

O=C(Cc1ccccc1)c1cc(F)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.55
▸ HTT P42858 5/20 0.55
▸ MAPT P10636 5/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ TP53 P04637 1/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ MAOB P27338 2/20 0.51
▸ XBP1 P17861 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ AR P10275 1/20 0.47
▸ HNF4A P41235 1/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ HPGD P15428 3/20 0.46
▸ GAA P10253 1/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ ALOX12 P18054 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29895835 0.89 HTT (0.50) LMNAHTTMAPTKDM4ETP53
SCHEMBL150248 0.89 HTT (0.50) LMNAHTTMAPTKDM4ETP53
SCHEMBL29586110 0.87 LMNA (0.67) LMNAHTTMAPTKDM4ETP53
SCHEMBL9061935 0.83 ESR1 (0.59) LMNAHTTMAPTMAPK1SMN1; SMN2
SCHEMBL1515773 0.81 CES2 (0.53) LMNAHTTMAPTKDM4ETP53
SCHEMBL29980324 0.81 LMNA (0.49) LMNAHTTMAPTKDM4ETP53
SCHEMBL11131 0.81 ALDH1A1 (0.64) LMNAHTTMAPTKDM4ETP53
SCHEMBL16322177 0.80 LMNA (0.77) LMNAHTTMAPTKDM4ETP53
SCHEMBL149097 0.80 GSTA1 (0.56) LMNAHTTMAPTKDM4EALOX15
SCHEMBL11069363 0.80 CSNK2A1 (0.58) LMNAHTTMAPTKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS AG (CH) 2022-10-25 — — US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
EP-2844647-B1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS S A (CH) 2020-07-22 — — EP disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 — — US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP disclosed
US-20190038634-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2019-02-07 — — US disclosed
US-10130635-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS SA (CH) 2018-11-20 — — US disclosed
US-20180098994-A9 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2018-04-12 — — US disclosed
US-20150087699-A1 NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2015-03-26 — — US disclosed
EP-2844647-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS Rhizen Pharmaceuticals S.A. (CH) 2015-03-11 — — EP disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 — — US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
WO-2013164801-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS SA (CH) 2013-11-07 — — WO disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed
EP-0336886-A1 Thio compounds CIBA-GEIGY AG (CH) 1989-10-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 LMNA 1935/4885HTT 2231/4885MAPT 2596/4885
US-20190038634-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 LMNA 897/4885HTT 2015/4885MAPT 3351/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB LMNA 2326/4885HTT 3125/4885MAPT 2989/4885
US-20150087699-A1 NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 LMNA 1177/4885HTT 2754/4885MAPT 3286/4885
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals CYP4B1, ADH1A, CYP1A2 LMNA 897/4885HTT 2015/4885MAPT 3351/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB LMNA 2326/4885HTT 3125/4885MAPT 2989/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB LMNA 2326/4885HTT 3125/4885MAPT 2989/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB LMNA 2326/4885HTT 3125/4885MAPT 2989/4885
US-20180098994-A9 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 LMNA 897/4885HTT 2015/4885MAPT 3351/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A LMNA 1277/4885HTT 3291/4885MAPT 3674/4885
US-10130635-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals CYP4B1, ADH1A, CYP1A2 LMNA 897/4885HTT 2015/4885MAPT 3351/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB LMNA 2326/4885HTT 3125/4885MAPT 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.